Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: January 2009
-
By Donald Zuhn — In an interview with TechJournal South, Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood discussed the state of the biotech industry and the biotech issues the new Administration will be facing in the coming year (see "BIO President Sees Biotech Industry Challenges for New Administration"). Mr. Greenwood told the…
-
By Donald Zuhn — Last week, Science Progress, a semi-annual journal published by the Center for American Progress, a liberal think tank headed by John Podesta, former White House Chief of Staff under President Clinton (as well as recent co-chairman of the Obama-Biden transition team), issued a series of reports on the U.S. patent…
-
By Kevin E. Noonan — President Obama, through his chief of staff Rahm Emanuel (at right), has acted swiftly to stall implementation of the spate of rulemaking by the outgoing Bush Administration. In the last days of the last administration, several rules concerning important, sensitive, and controversial issues were promulgated by various branches of…
-
By Donald Zuhn — Earlier today, in a historic moment on the steps of the U.S. Capitol, Barack Hussein Obama was sworn in as the 44th President of the United States. Tomorrow, his Administration will begin to tackle the many serious issues that face our country (the Administration's agenda can be found on the…
-
By Kevin E. Noonan — The recent changes in Chinese patent law have not received universal approval from a number of Western groups. Two of these, the Intellectual Property Owners Association (IPO) and the Biotechnology Industry Organization, have taken different tacks to the same end: disapproval of changes seen as harming their members' interests.…
-
By Kevin E. Noonan — One of our foreign associates in China, Vivien Chan & Co., informs us of a number of important changes in Chinese patent law adopted by the People's Congress on December 27th. The following new rules for patent practice will come into force in China on October 1, 2009: • …
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Oscient Pharmaceuticals Corp. et al. v. Lupin Ltd. et al.1:09-cv-00083; filed January 14, 2009 in the District Court of Maryland Infringement of…
-
January 20-21, 2009 – Bio/Pharmaceutical Summit on Legal and Regulatory Product Lifecycle Strategies*** (Center for Business Intelligence) – Baltimore, MD January 26-27, 2009 – Structuring and Negotiating Pharma & Biotech Collaborative Agreements (C5) – London, England January 27-28, 2009 – ITC Litigation (American Conference Institute)*** – Washington, DC January 28-29, 2009 – 6th National Conference…
-
By Jason Derry —Medicines Co. to Buy Targanta The Medicines Company and Targanta Therapeutics have announced that Medicines Co. will buy Targanta for $42 million. Medicines Co. has agreed to increase the purchase price by an additional $1.20 a share if Targanta's oritavancin, a product for treating skin infections, is approved by the FDA…
-
By Donald Zuhn — Yesterday, the Manufacturing Alliance on Patent Policy (MAPP) released a report which indicates that the apportionment of damages provisions found in the Senate (S. 1145) and House (H.R. 1908) patent reform bills would have several adverse effects. The apportionment of damages provisions in these bills attempt to apportion the value…
Patent Docs 